We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

L’Oreal, Organovo Partner to Produce 3D Printed Skin

L’Oreal, Organovo Partner to Produce 3D Printed Skin

L’Oreal, Organovo Partner to Produce 3D Printed Skin

L’Oreal, Organovo Partner to Produce 3D Printed Skin

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "L’Oreal, Organovo Partner to Produce 3D Printed Skin"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

L’Oreal is partnering with bioprinting startup Organovo to engineer 3D printed skin tissue to test products and perform other advanced research, the companies announced in a joint statement this week.

Organovo previously partnered with Merck to print liver and kidney tissues. The company anticipates its kidney tissue will be ready for release in the second half of 2016.

L’Oreal has been producing skin samples from donated tissues since the 1980s to avoid animal testing, Bloomberg reported.  But the cosmetics giant, which currently grows more than 100,000 skin samples per year, according to Bloomberg, wants more derma and intends to automate and help speed up production over the next five years with Organovo’s help.

“Research for the project will take place in Organovo’s labs and L’Oreal’s new California research center. L’Oreal will provide skin expertise and all the initial funding, while Organovo, which is already working with such companies as Merck to print liver and kidney tissues, will provide the technology,” the Bloomberg report said.

Both companies will retain rights to the tissue in different ways. L'Oreal uses about half of the skin samples it currently produces, available in nine varieties that span ages and ethnicities, while the other half is sold to pharmaceutical companies and others in the cosmetics industry, Bloomberg reported.

“Some of the biggest potential advantages are the speed of production as well as the level of precision that 3D printing can achieve,” Give Balooch, global vice president of L’Oreal’s technology incubator said in an email to the Washington Post.  “L’Oreal’s focus right now is not to increase the quantity of the skin we produce but instead to continue to build on the accuracy and consistent replication of the skin engineering process.”

The Verge writes Organovo’s manufacturing process entails detecting essentially the key building blocks of the specified tissue and concocting a specialized “bio-ink” to begin building the tissue in vertical layers. By comparison, L’Oreal’s scientists break down skin tissue into basic cells, sustain those cells on a special diet, and grow them in a setting that imitates the human body taking about a week to form.